Lv6
2660 积分 2023-01-17 加入
Discovery of Tetracyclic Derivatives as Highly Potent, Selective, and Bioavailable PKMYT1 Inhibitors for Cancer Therapy
21天前
已完结
STX-478, RLY-2608, and LOXO-783: third-generation PIK3CA mutant-selective allosteric inhibitors
26天前
已完结
Discovery of a Novel Macrocyclic Noncovalent CDK7 Inhibitor for Cancer Therapy
1个月前
已完结
Discovery of an Androgen Receptor Degrader Featuring a Pyridazinyl Glutarimide CRBN-Binding Motif for Transdermal Treatment of Androgenetic Alopecia
1个月前
已完结
Discovery of a Highly Potent and Selective Tyrosine Kinase 2 (TYK2) Degrader with In Vivo Therapeutic Efficacy in a Murine Psoriasis Model
2个月前
已完结
Discovery of AZD8421: A Potent CDK2 Inhibitor with Selectivity Against Other CDK Family Members and the Human Kinome
2个月前
已完结
Discovery of (4-Pyrazolyl)-2-aminopyrimidines as Potent and Selective Inhibitors of Cyclin-Dependent Kinase 2
3个月前
已完结
From KRAS G12D to Pan-KRAS Inhibitors─A Journey Enabled by Synthetic Innovation and Structure-Based Drug Design
3个月前
已完结
Practical and Scalable Method for Manufacturing AZD4604, A Potent and Selective JAK1 Inhibitor
3个月前
已完结
A patent review of anticancer CDK2 inhibitors (2017–present)
4个月前
已完结
皖公网安备34019202002308
